Celltrion Celebrates Interchangeability Designation For Humira Biosimilar In The US

Also, Biosimilar Approvals In Australia And Supply Bids In Latin America

Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.

Logo of the US Food and Drug Administration
(Shutterstock)

More from Biosimilars

More from Generics Bulletin